UK collaboration for magnetotherapy technology:
This article was originally published in Clinica
Executive Summary
Biotech firm Celltech has formed a UK collaboration to develop a magnetic-guided antibody therapy for treating cancer. The project will initially run for two years and will evaluate the use of Celltech's targeted antibody therapy in treating tumour cells with magnetically controlled nanoparticles. Researchers from the University of Durham will run the trials and will also be responsible for producing and coating the nanoparticles. Oxford Instruments Molecular Biotools will develop the external magnetic technology used to mediate the magnetically attached antibodies. Professor Mike Eaton, head of Celltech Antibody Chemistry, told Clinica that the antibody-targeted magnetotherapy could be available in clinics within the next five years. However, he declined to disclose any information about the nanoparticles used in the trials.